Mensch und Maschine Software SE
- WKN: 658080
- ISIN: DE0006580806
- Land: Germany
Nachricht vom 11.10.2021 | 09:56
M+M: Ecology and Economy in full harmony
DGAP-News: Mensch und Maschine Software SE
/ Key word(s): Sustainability
- New photovoltaic system on headquarters roof
- Annual solar power production rising to ~140 MWh
Wessling, October 11, 2021 - Mensch und Maschine Software SE (MUM - ISIN DE0006580806), a CAD/CAM specialist company, significantly augmented regenerative power production activities. In September, an approx. 1,500 square meter photovoltaic system was installed on the roof of M+M headquarters in Wessling. Altogether M+M group is now producing approx. 140 MWh solar power p.a. by using all suitable roof surfaces in corporate ownership for regenerative power production.
As early as 2011 the first plant with nearly 25 MWh annual output had been installed on the M+M Training Center in Wiesbaden. In the years 2019/20 new buildings were completed by group members SOFiSTiK in Nuremberg (with photovoltaic plus geothermal energy) and DATAflor in Goettingen (with photovoltaic plus cogeneration unit).
As replacing coal-fired by solar electricity saves around one kilogram CO2 emissions per kWh (Source: strom-report.de), M+M thus is achieving approx. 140 metric tons of CO2 savings per year. Moreover, ecology and economy are in full harmony: The new power plant on the headquarters roof will have amortized after approx. 10 years.
|Company:||Mensch und Maschine Software SE|
|Argelsrieder Feld 5|
|Phone:||+49 (0)815 3933-0|
|Fax:||+49 (0)815 3933-100|
|Listed:||Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Hamburg, Munich (m:access), Stuttgart, Tradegate Exchange|
|EQS News ID:||1239691|
|End of News||DGAP News Service|
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
04. Dezember 07:15 Bitcoin & Co: Brutaler Abverkauf – ist die Party jetzt vorbei?
04. Dezember 08:00 Top-Tipp Derivate: Luxus in der Warteschleife
04. Dezember 08:05 China-Aktien, Bitcoin & Co: Risiko-Assets werden verkauft
04. Dezember 08:45 Deutsche Telekom: 50 Prozent Potenzial - wann gelingt die Trendwende?
05. Dezember 07:00 Diese Token sind heißer als Bitcoin
News im Fokus
Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an
03. Dezember 2021, 07:03
FY 2020/2021 Financial Results
16. Dezember 2021
Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen
02. Dezember 2021